Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 165 entries
Sorted by: Best Match Show Resources per page
Hydrogen Bonds Involving Cavity NH Protons Drives Supramolecular Oligomerization of Amido-Corroles.

Chemistry (Weinheim an der Bergstrasse, Germany)

Orłowski R, Tasior M, Staszewska-Krajewska O, Dobrzycki Ł, Schilf W, Ventura B, Cyrański MK, Gryko DT.
PMID: 28514507
Chemistry. 2017 Jul 26;23(42):10195-10204. doi: 10.1002/chem.201701674. Epub 2017 Jul 06.

trans-A

Cite
Orłowski R, Tasior M, Staszewska-Krajewska O, et al. Hydrogen Bonds Involving Cavity NH Protons Drives Supramolecular Oligomerization of Amido-Corroles. Chemistry. 2017;23(42):10195-10204doi: 10.1002/chem.201701674.
Orłowski, R., Tasior, M., Staszewska-Krajewska, O., Dobrzycki, �. �., Schilf, W., Ventura, B., Cyrański, M. K., & Gryko, D. T. (2017). Hydrogen Bonds Involving Cavity NH Protons Drives Supramolecular Oligomerization of Amido-Corroles. Chemistry (Weinheim an der Bergstrasse, Germany), 23(42), 10195-10204. https://doi.org/10.1002/chem.201701674
Orłowski, Rafał, et al. "Hydrogen Bonds Involving Cavity NH Protons Drives Supramolecular Oligomerization of Amido-Corroles." Chemistry (Weinheim an der Bergstrasse, Germany) vol. 23,42 (2017): 10195-10204. doi: https://doi.org/10.1002/chem.201701674
Orłowski R, Tasior M, Staszewska-Krajewska O, Dobrzycki Ł, Schilf W, Ventura B, Cyrański MK, Gryko DT. Hydrogen Bonds Involving Cavity NH Protons Drives Supramolecular Oligomerization of Amido-Corroles. Chemistry. 2017 Jul 26;23(42):10195-10204. doi: 10.1002/chem.201701674. Epub 2017 Jul 06. PMID: 28514507.
Copy Download .nbib Format: NLM
Novel intra-alveolar drug carrier as a functional dressing for the alveolar osteitis treatment.

Journal of controlled release : official journal of the Controlled Release Society

Nowak KM, Szymborski T, Orłowska J, Rudnicka K, Chmiela M, Bodek KH.
PMID: 27005206
J Control Release. 2015 Sep 10;213:e65-6. doi: 10.1016/j.jconrel.2015.05.108. Epub 2015 Aug 19.

No abstract available.

Cite
Nowak KM, Szymborski T, Orłowska J, et al. Novel intra-alveolar drug carrier as a functional dressing for the alveolar osteitis treatment. J Control Release. 2015;213:e65-6doi: 10.1016/j.jconrel.2015.05.108.
Nowak, K. M., Szymborski, T., Orłowska, J., Rudnicka, K., Chmiela, M., & Bodek, K. H. (2015). Novel intra-alveolar drug carrier as a functional dressing for the alveolar osteitis treatment. Journal of controlled release : official journal of the Controlled Release Society, 213e65-6. https://doi.org/10.1016/j.jconrel.2015.05.108
Nowak, Karolina Maria, et al. "Novel intra-alveolar drug carrier as a functional dressing for the alveolar osteitis treatment." Journal of controlled release : official journal of the Controlled Release Society vol. 213 (2015): e65-6. doi: https://doi.org/10.1016/j.jconrel.2015.05.108
Nowak KM, Szymborski T, Orłowska J, Rudnicka K, Chmiela M, Bodek KH. Novel intra-alveolar drug carrier as a functional dressing for the alveolar osteitis treatment. J Control Release. 2015 Sep 10;213:e65-6. doi: 10.1016/j.jconrel.2015.05.108. Epub 2015 Aug 19. PMID: 27005206.
Copy Download .nbib Format: NLM
Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study.

Clinical and experimental hepatology

Flisiak R, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K, Tuchendler E, Madej G, Piekarska A, Jabłkowski M, Deroń Z, Mazur W, Kaczmarczyk M, Janczewska E, Pisula A, Smykał J, Nowak K, Matukiewicz M, Halota W, Wernik J, Sikorska K, Mozer-Lisewska I, Rozpłochowski B, Garlicki A, Tomasiewicz K, Krzowska-Firych J, Baka-Ćwierz B, Kryczka W, Zarębska-Michaluk D, Olszok I, Boroń-Kaczmarska A, Sobala-Szczygieł B, Szlauer B, Korcz-Ondrzejek B, Sieklucki J, Pleśniak R, Ruszała A, Postawa-Kłosińska B, Citko J, Lachowicz-Wawrzyniak A, Musialik J, Jezierska E, Dobracki W, Dobracka B, Hałubiec J, Krygier R, Strokowska A, Chomczyk W, Witczak-Malinowska K.
PMID: 28856278
Clin Exp Hepatol. 2016 Dec;2(4):138-143. doi: 10.5114/ceh.2016.63870. Epub 2016 Nov 28.

THE AIM OF THE STUDY: Was to analyze the efficacy achieved with regimens available for chronic hepatitis C (CHC) in Poland between 2013 and 2016.MATERIAL AND METHODS: Data were collected from 29 centers and included 6786 patients with available...

Cite
Flisiak R, Pogorzelska J, Berak H, et al. Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study. Clin Exp Hepatol. 2016;2(4):138-143doi: 10.5114/ceh.2016.63870.
Flisiak, R., Pogorzelska, J., Berak, H., Horban, A., Orłowska, I., Simon, K., Tuchendler, E., Madej, G., Piekarska, A., Jabłkowski, M., Deroń, Z., Mazur, W., Kaczmarczyk, M., Janczewska, E., Pisula, A., Smykał, J., Nowak, K., Matukiewicz, M., Halota, W., Wernik, J., Sikorska, K., Mozer-Lisewska, I., Rozpłochowski, B., Garlicki, A., Tomasiewicz, K., Krzowska-Firych, J., Baka-Ćwierz, B., Kryczka, W., Zarębska-Michaluk, D., Olszok, I., Boroń-Kaczmarska, A., Sobala-Szczygieł, B., Szlauer, B., Korcz-Ondrzejek, B., Sieklucki, J., Pleśniak, R., Ruszała, A., Postawa-Kłosińska, B., Citko, J., Lachowicz-Wawrzyniak, A., Musialik, J., Jezierska, E., Dobracki, W., Dobracka, B., Hałubiec, J., Krygier, R., Strokowska, A., Chomczyk, W., & Witczak-Malinowska, K. (2016). Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study. Clinical and experimental hepatology, 2(4), 138-143. https://doi.org/10.5114/ceh.2016.63870
Flisiak, Robert, et al. "Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study." Clinical and experimental hepatology vol. 2,4 (2016): 138-143. doi: https://doi.org/10.5114/ceh.2016.63870
Flisiak R, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K, Tuchendler E, Madej G, Piekarska A, Jabłkowski M, Deroń Z, Mazur W, Kaczmarczyk M, Janczewska E, Pisula A, Smykał J, Nowak K, Matukiewicz M, Halota W, Wernik J, Sikorska K, Mozer-Lisewska I, Rozpłochowski B, Garlicki A, Tomasiewicz K, Krzowska-Firych J, Baka-Ćwierz B, Kryczka W, Zarębska-Michaluk D, Olszok I, Boroń-Kaczmarska A, Sobala-Szczygieł B, Szlauer B, Korcz-Ondrzejek B, Sieklucki J, Pleśniak R, Ruszała A, Postawa-Kłosińska B, Citko J, Lachowicz-Wawrzyniak A, Musialik J, Jezierska E, Dobracki W, Dobracka B, Hałubiec J, Krygier R, Strokowska A, Chomczyk W, Witczak-Malinowska K. Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study. Clin Exp Hepatol. 2016 Dec;2(4):138-143. doi: 10.5114/ceh.2016.63870. Epub 2016 Nov 28. PMID: 28856278; PMCID: PMC5497429.
Copy Download .nbib Format: NLM
Self-assembling corroles.

Chemical communications (Cambridge, England)

Orłowski R, Vakuliuk O, Gullo MP, Danylyuk O, Ventura B, Koszarna B, Tarnowska A, Jaworska N, Barbieri A, Gryko DT.
PMID: 25876752
Chem Commun (Camb). 2015 May 14;51(39):8284-7. doi: 10.1039/c5cc01306b.

trans-A2B-corroles bearing -OCH2CONHR groups at the ortho position of the meso-phenyl substituent undergo self-organization both in the solid state as well as in solution. The lack of additional donor atoms induces sheet formation, but if the pyridine unit is...

Cite
Orłowski R, Vakuliuk O, Gullo MP, et al. Self-assembling corroles. Chem Commun (Camb). 2015;51(39):8284-7doi: 10.1039/c5cc01306b.
Orłowski, R., Vakuliuk, O., Gullo, M. P., Danylyuk, O., Ventura, B., Koszarna, B., Tarnowska, A., Jaworska, N., Barbieri, A., & Gryko, D. T. (2015). Self-assembling corroles. Chemical communications (Cambridge, England), 51(39), 8284-7. https://doi.org/10.1039/c5cc01306b
Orłowski, Rafał, et al. "Self-assembling corroles." Chemical communications (Cambridge, England) vol. 51,39 (2015): 8284-7. doi: https://doi.org/10.1039/c5cc01306b
Orłowski R, Vakuliuk O, Gullo MP, Danylyuk O, Ventura B, Koszarna B, Tarnowska A, Jaworska N, Barbieri A, Gryko DT. Self-assembling corroles. Chem Commun (Camb). 2015 May 14;51(39):8284-7. doi: 10.1039/c5cc01306b. PMID: 25876752.
Copy Download .nbib Format: NLM
Usefulness of the Obesity Surgery Mortality Risk Score (OR-MRS) in choosing the laparoscopic bariatric procedure.

Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques

Orłowski M, Janik MR, Paśnik K, Jędrzejewski E.
PMID: 26240623
Wideochir Inne Tech Maloinwazyjne. 2015 Jul;10(2):233-6. doi: 10.5114/wiitm.2015.52390. Epub 2015 Jun 19.

INTRODUCTION: The most popular scale to stratify the postoperative risk is the Obesity Surgery Mortality Risk Score (OS-MRS). The design and ease of interpretation make the scale a potential tool for clinical use.AIM: To evaluate the usefulness of the...

Cite
Orłowski M, Janik MR, Paśnik K, et al. Usefulness of the Obesity Surgery Mortality Risk Score (OR-MRS) in choosing the laparoscopic bariatric procedure. Wideochir Inne Tech Maloinwazyjne. 2015;10(2):233-6doi: 10.5114/wiitm.2015.52390.
Orłowski, M., Janik, M. R., Paśnik, K., & Jędrzejewski, E. (2015). Usefulness of the Obesity Surgery Mortality Risk Score (OR-MRS) in choosing the laparoscopic bariatric procedure. Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques, 10(2), 233-6. https://doi.org/10.5114/wiitm.2015.52390
Orłowski, Mikołaj, et al. "Usefulness of the Obesity Surgery Mortality Risk Score (OR-MRS) in choosing the laparoscopic bariatric procedure." Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques vol. 10,2 (2015): 233-6. doi: https://doi.org/10.5114/wiitm.2015.52390
Orłowski M, Janik MR, Paśnik K, Jędrzejewski E. Usefulness of the Obesity Surgery Mortality Risk Score (OR-MRS) in choosing the laparoscopic bariatric procedure. Wideochir Inne Tech Maloinwazyjne. 2015 Jul;10(2):233-6. doi: 10.5114/wiitm.2015.52390. Epub 2015 Jun 19. PMID: 26240623; PMCID: PMC4520850.
Copy Download .nbib Format: NLM
Rapid Screening of Antimicrobial Synthetic Peptides.

International journal of peptide research and therapeutics

Jaskiewicz M, Orlowska M, Olizarowicz G, Migon D, Grzywacz D, Kamysz W.
PMID: 27226784
Int J Pept Res Ther. 2016;22:155-161. doi: 10.1007/s10989-015-9494-4. Epub 2015 Sep 28.

Increasing resistance to conventional antibiotics among microorganisms is one of the leading problems of medicine nowadays. Antimicrobial peptides are compounds exhibiting both antibacterial and antifungal activities. However, it is difficult to predict whether a designed new compound would exhibit...

Cite
Jaskiewicz M, Orlowska M, Olizarowicz G, et al. Rapid Screening of Antimicrobial Synthetic Peptides. Int J Pept Res Ther. 2015;22:155-161doi: 10.1007/s10989-015-9494-4.
Jaskiewicz, M., Orlowska, M., Olizarowicz, G., Migon, D., Grzywacz, D., & Kamysz, W. (2016). Rapid Screening of Antimicrobial Synthetic Peptides. International journal of peptide research and therapeutics, 22155-161. https://doi.org/10.1007/s10989-015-9494-4
Jaskiewicz, Maciej, et al. "Rapid Screening of Antimicrobial Synthetic Peptides." International journal of peptide research and therapeutics vol. 22 (2016): 155-161. doi: https://doi.org/10.1007/s10989-015-9494-4
Jaskiewicz M, Orlowska M, Olizarowicz G, Migon D, Grzywacz D, Kamysz W. Rapid Screening of Antimicrobial Synthetic Peptides. Int J Pept Res Ther. 2016;22:155-161. doi: 10.1007/s10989-015-9494-4. Epub 2015 Sep 28. PMID: 27226784; PMCID: PMC4854934.
Copy Download .nbib Format: NLM
Cost of Pharmacotherapy in Polish Patients With Rheumatoid Arthritis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Szafraniec-Burylo S, Orlewska E.
PMID: 27200862
Value Health. 2014 Nov;17(7):A383. doi: 10.1016/j.jval.2014.08.2631. Epub 2014 Oct 26.

No abstract available.

Cite
Szafraniec-Burylo S, Orlewska E. Cost of Pharmacotherapy in Polish Patients With Rheumatoid Arthritis. Value Health. 2014;17(7):A383doi: 10.1016/j.jval.2014.08.2631.
Szafraniec-Burylo, S., & Orlewska, E. (2014). Cost of Pharmacotherapy in Polish Patients With Rheumatoid Arthritis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A383. https://doi.org/10.1016/j.jval.2014.08.2631
Szafraniec-Burylo, S, and Orlewska, E. "Cost of Pharmacotherapy in Polish Patients With Rheumatoid Arthritis." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A383. doi: https://doi.org/10.1016/j.jval.2014.08.2631
Szafraniec-Burylo S, Orlewska E. Cost of Pharmacotherapy in Polish Patients With Rheumatoid Arthritis. Value Health. 2014 Nov;17(7):A383. doi: 10.1016/j.jval.2014.08.2631. Epub 2014 Oct 26. PMID: 27200862.
Copy Download .nbib Format: NLM
Economic aspects in medical decision-making.

Transplantation proceedings

Orlewska E.
PMID: 12947913
Transplant Proc. 2003 May;35(3):1227-9. doi: 10.1016/s0041-1345(03)00200-8.

No abstract available.

Cite
Orlewska E. Economic aspects in medical decision-making. Transplant Proc. 2003;35(3):1227-9doi: 10.1016/s0041-1345(03)00200-8.
Orlewska, E. (2003). Economic aspects in medical decision-making. Transplantation proceedings, 35(3), 1227-9. https://doi.org/10.1016/s0041-1345(03)00200-8
Orlewska, E. "Economic aspects in medical decision-making." Transplantation proceedings vol. 35,3 (2003): 1227-9. doi: https://doi.org/10.1016/s0041-1345(03)00200-8
Orlewska E. Economic aspects in medical decision-making. Transplant Proc. 2003 May;35(3):1227-9. doi: 10.1016/s0041-1345(03)00200-8. PMID: 12947913.
Copy Download .nbib Format: NLM
Cost-effectiveness of pegylated IFN-alpha2b and -2a and ribavirin for chronic hepatitis C treatment.

Expert review of pharmacoeconomics & outcomes research

Orlewska E.
PMID: 19807543
Expert Rev Pharmacoecon Outcomes Res. 2004 Oct;4(5):495-504. doi: 10.1586/14737167.4.5.495.

Pegylated interferon-alpha(2a) (Pegasys, Roche) and pegylated interferon-alpha(2b) (Peg-Intron, Schering-Plough) with ribavirin (Copegus, Roche; Rebetol, Schering-Plough) is now acknowledged as the therapy of choice for chronic hepatitis C. This article reviews the existing evidence concerning the cost-effectiveness of pegylated interferon...

Cite
Orlewska E. Cost-effectiveness of pegylated IFN-alpha2b and -2a and ribavirin for chronic hepatitis C treatment. Expert Rev Pharmacoecon Outcomes Res. 2004;4(5):495-504doi: 10.1586/14737167.4.5.495.
Orlewska, E. (2004). Cost-effectiveness of pegylated IFN-alpha2b and -2a and ribavirin for chronic hepatitis C treatment. Expert review of pharmacoeconomics & outcomes research, 4(5), 495-504. https://doi.org/10.1586/14737167.4.5.495
Orlewska, Ewa. "Cost-effectiveness of pegylated IFN-alpha2b and -2a and ribavirin for chronic hepatitis C treatment." Expert review of pharmacoeconomics & outcomes research vol. 4,5 (2004): 495-504. doi: https://doi.org/10.1586/14737167.4.5.495
Orlewska E. Cost-effectiveness of pegylated IFN-alpha2b and -2a and ribavirin for chronic hepatitis C treatment. Expert Rev Pharmacoecon Outcomes Res. 2004 Oct;4(5):495-504. doi: 10.1586/14737167.4.5.495. PMID: 19807543.
Copy Download .nbib Format: NLM
Hyperplastic polyposis syndrome and the risk of colorectal cancer.

Gut

Orlowska J.
PMID: 21636642
Gut. 2012 Mar;61(3):470-1; author reply 471-2. doi: 10.1136/gutjnl-2011-300141. Epub 2011 Jun 02.

No abstract available.

Cite
Orlowska J. Hyperplastic polyposis syndrome and the risk of colorectal cancer. Gut. 2011;61(3):470-1; author reply 471-2doi: 10.1136/gutjnl-2011-300141.
Orlowska, J. (2012). Hyperplastic polyposis syndrome and the risk of colorectal cancer. Gut, 61(3), 470-1; author reply 471-2. https://doi.org/10.1136/gutjnl-2011-300141
Orlowska, Janina. "Hyperplastic polyposis syndrome and the risk of colorectal cancer." Gut vol. 61,3 (2012): 470-1; author reply 471-2. doi: https://doi.org/10.1136/gutjnl-2011-300141
Orlowska J. Hyperplastic polyposis syndrome and the risk of colorectal cancer. Gut. 2012 Mar;61(3):470-1; author reply 471-2. doi: 10.1136/gutjnl-2011-300141. Epub 2011 Jun 02. PMID: 21636642.
Copy Download .nbib Format: NLM
Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies?.

Expert review of pharmacoeconomics & outcomes research

Orlewska E.
PMID: 20528550
Expert Rev Pharmacoecon Outcomes Res. 2006 Apr;6(2):145-54. doi: 10.1586/14737167.6.2.145.

The purpose of this article is to provide a critical evaluation of the available literature describing the economic burden of multiple sclerosis and to assess the gaps in information. The studies included in this review describe costs in patients...

Cite
Orlewska E. Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies?. Expert Rev Pharmacoecon Outcomes Res. 2006;6(2):145-54doi: 10.1586/14737167.6.2.145.
Orlewska, E. (2006). Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies?. Expert review of pharmacoeconomics & outcomes research, 6(2), 145-54. https://doi.org/10.1586/14737167.6.2.145
Orlewska, Ewa. "Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies?." Expert review of pharmacoeconomics & outcomes research vol. 6,2 (2006): 145-54. doi: https://doi.org/10.1586/14737167.6.2.145
Orlewska E. Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies?. Expert Rev Pharmacoecon Outcomes Res. 2006 Apr;6(2):145-54. doi: 10.1586/14737167.6.2.145. PMID: 20528550.
Copy Download .nbib Format: NLM
Significance of CDKN2A gene A148T variant in patients with bladder cancer.

Central European journal of urology

Borkowska E, Jędrzejczyk A, Kruk A, Pietrusiński M, Traczyk M, Rożniecki M, Kałużewski B.
PMID: 24578887
Cent European J Urol. 2011;64(3):168-74. doi: 10.5173/ceju.2011.03.art17. Epub 2011 Sep 06.

OBJECTIVES: The A148T polymorphism of CDKN2A gene is observed in various neoplasms with the incidence rate of 3-35%, however, rather little is known either about the frequency of its occurrence or of its significance in urinary bladder carcinoma.MATERIALS AND...

Cite
Borkowska E, Jędrzejczyk A, Kruk A, et al. Significance of CDKN2A gene A148T variant in patients with bladder cancer. Cent European J Urol. 2011;64(3):168-74doi: 10.5173/ceju.2011.03.art17.
Borkowska, E., Jędrzejczyk, A., Kruk, A., Pietrusiński, M., Traczyk, M., Rożniecki, M., & Kałużewski, B. (2011). Significance of CDKN2A gene A148T variant in patients with bladder cancer. Central European journal of urology, 64(3), 168-74. https://doi.org/10.5173/ceju.2011.03.art17
Borkowska, Edyta, et al. "Significance of CDKN2A gene A148T variant in patients with bladder cancer." Central European journal of urology vol. 64,3 (2011): 168-74. doi: https://doi.org/10.5173/ceju.2011.03.art17
Borkowska E, Jędrzejczyk A, Kruk A, Pietrusiński M, Traczyk M, Rożniecki M, Kałużewski B. Significance of CDKN2A gene A148T variant in patients with bladder cancer. Cent European J Urol. 2011;64(3):168-74. doi: 10.5173/ceju.2011.03.art17. Epub 2011 Sep 06. PMID: 24578887; PMCID: PMC3921733.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 165 entries